Yıl: 2021 Cilt: 46 Sayı: 4 Sayfa Aralığı: 455 - 460 Metin Dili: İngilizce DOI: 10.1515/tjb-2020-0103 İndeks Tarihi: 24-06-2022

Association of CYP2D6*4 gene polymorphism with early papillary thyroid carcinoma

Öz:
Objectives: CYP2D6 is highly polymorphic and a common variant CYP2D6*4 results in the generation of poor metabolizer enzyme. The CYP2D6*4 variant has been associated with altered susceptibility to several cancers. The aim of the present case-control study aims to investigate the association between CYP2D6*4 polymorphism and the risk of papillary thyroid carcinoma (PTC). Materials and methods: Astudy population of 97 caseswith PTC and 120 controls were included in the study. Genotyping was done by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method to detect the presence of CYP2D6*4. Results: The CYP2D6*4 was associated with significantly increased PTC risk when compared with controls (odds ratio [OR]=1.995, 95% confidence interval [CI]=1.060–3.752, p=0.031). Besides, CYP2D6*4 allele frequency was higher in PTC patients with age ≤50 years when compared to those with age >50 (OR=2.380, 95% CI=1.191–4.755, p=0.013). CYP2D6*4 allele frequency was higher in patients who had encapsulated tumors, but it was not statistically significant (p=0.111). No relationship was found between CYP2D6*4 and PTC variants or between early (I/II) and late (III/IV) tumor stages. Conclusions: Our findings indicate that the poor metabolizer CYP2D6*4 genotype may be a risk factor, especially in early PTC development. Further research with larger groups is required for the confirmation of our consequences.
Anahtar Kelime:

CYP2D6*4 gen polimorfizminin erken papiller tiroid karsinomu ile ilişkisi

Öz:
Amaç: CYP2D6 oldukça polimorfiktir ve yaygın bir varyant olan CYP2D6*4, zayıf metabolizör enziminin üretilmesine neden olur. CYP2D6*4 varyantı birçok kansere yatkınlıkla ilişkilendirilmiştir. Bu vaka kontrol çalışmasında CYP2D6*4 polimorfizmi ile papiller tiroid karsinomu (PTK) arasındaki ilişkinin araştırılması amaçlanmıştır. Gereç ve Yöntemler: Çalışmaya 97 PTK ve 120 kontrol olgusu dahil edildi. CYP2D6*4’ün varlığını saptamak için PCR-RFLP yöntemiyle genotiplendirme yapıldı. Bulgular: CYP2D6*4’ün kontrollerle karşılaştırıldığında anlamlı düzeyde artmış PTK riski ile ilişkili olduğu bulundu (OR=1.995, %95 CI=1.060–3.752, p=0.031). Ayrıca, CYP2D6*4 alel sıklığı yaşı ≤50 olan PTK hastalarında yaşı >50 olanlara göre daha yüksekti (OR=2.380,%95 CI=1.191–4.755, p=0.013). Kapsüllü tümörleri olan hastalarda CYP2D6*4 alel sıklığı daha yüksekti, ancak istatistiksel olarak anlamlı değildi (p=0.111). CYP2D6*4 ve PTK varyantları arasında veya erken (I/II) ve geç (III/IV) tümör evreleri arasında ilişki bulunmadı. Sonuç: Bulgularımız, zayıf metabolizör CYP2D6*4 genotipinin, özellikle erken yaş PTK gelişimi için bir risk faktörü olabileceğine işaret etmektedir. Sonuçlarımızın doğrulanması için daha büyük gruplarla araştırma yapılması gerekmektedir.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501–11.
  • 2. Katoh H, Yamashita K, Enomoto T, Watanabe M. Classification and general considerations of thyroid cancer. Ann Clin Pathol 2015;3: 1045.
  • 3. Schmidbauer B, Menhart K, Hellwig D, Grosse J. Differentiated thyroid cancer-treatment: state of the art. Int J Mol Sci 2017;18: E1292.
  • 4. Zaballos MA, Santisteban P. Key signaling pathways in thyroid cancer. J Endocrinol 2017;235:R43–61.
  • 5. Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008;36:425–37.
  • 6. Nikiforov YE. Role of molecular markers in thyroid nodule management: then and now. Endocr Pract 2017;23:979–88.
  • 7. Guengerich FP. Cytochrome P450: what have we learned and what are the future issues? Drug Metab Rev 2004;36:159–97.
  • 8. Rychlik-Sych M, Skrętkowicz J. Drug metabolism. Farm Pol 2008; 64:51–60.
  • 9. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989;45:889–904.
  • 10. Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl- Carrillo M, Klein TE, et al. The pharmacogene variation (PharmVar) consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin Pharmacol Ther 2018;103: 399–401.
  • 11. Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med 2017;19:215–23.
  • 12. Del Tredici AL, Malhotra A, Dedek M, Espin F, Roach D, Zhu GD. Frequency of CYP2D6 alleles including structural variants in the United States. Front Pharmacol 2018;9:305.
  • 13. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenetics Genom 2007;17:93–101.
  • 14. Shukla P, Gupta D, Pant MC, Parmar D. CYP 2D6 polymorphism: a predictor of susceptibility and response to chemotherapy in head and neck cancer. J Canc Res Therapeut 2012;8:40–5.
  • 15. Silveira VS, Canalle R, Scrideli CA, Queiroz RGP, Tone LG. Role of the CYP2D6, EPHX1, MPO, and NQO1 genes in the susceptibility to acute lymphoblastic leukemia in Brazilian children. Environ Mol Mutagen 2010;51:48–56.
  • 16. Sobti RC, Onsory K, Al-Badran AI, Kaur P, Watanabe M, Krishan A, et al. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biol 2006;25:287–94.
  • 17. Thota K, Prasad K, Rao MVB. Detection of cytochrome P450 polymorphisms in breast cancer patients may impact on tamoxifen therapy. Asian Pac J Cancer Prev APJCP 2018;19: 343–50.
  • 18. Lemos MC, Carrilho F, Rodriguest F, Coutinho E, Gomes L, CarvalheiroM, et al. Genetic polymorphismof CYP2D6 influences susceptibility to papillary thyroid cancer. Clin Endocrinol 2007; 67:180–3.
  • 19. Dağlar-Aday A, Toptaş B, Öztürk T, Seyhan F, Saygılı N, Eronat AP, et al. Investigation of BRAF V600E mutation in papillary thyroid carcinoma and tumor-surrounding nontumoral tissues. DNA Cell Biol 2013;32:13–8.
  • 20. Meier PJ, Mueller HK, Dick B, Meyer UA. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Gastroenterology 1983;85:682–92.
  • 21. Schur BC, Bjerke J, Nuwayhid N, Wong SH. Genotyping of cytochrome P450 2D6 *3 and *4 mutations using conventional PCR*. Clin Chim Acta 2001;308:25–31.
  • 22. Dupont, WD, Plummer, WD. PS: power and sample size calculation. Available from: http://biostat.mc.vanderbilt.edu/ wiki/Main/PowerSampleSize [Updated 16.02.2018].
  • 23. Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med 2016;375:614–7.
  • 24. Raunio H, Kuusisto M, Juvonen RO, Pentikäinen OT. Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes. Front Pharmacol 2015;6:123.
  • 25. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, et al. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 1990;347:773–6.
  • 26. Gomes L, Lemos MC, Paiva I, Riberio C, CarvalheiroM, Regateiro FJ. Cyp2d6 genetic polymorphisms are associated with susceptibility to pituitary tumors. Acta Med Port 2005;18:339–44.
  • 27. Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA. Environmental and chemical carcinogenesis. Semin Canc Biol 2004;14(6):473–86.
  • 28. Ayesh R, Idle JR, Ritchie JC, Crothers MJ, Hetzel MR. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984;312:169–70.
  • 29. Ouerhani S, Marrakchi R, Bouhaha R, Ben Slama MR, Sfaxi M, Ayed M, et al. The role of CYP2D6*4 variant in bladder cancer susceptibility in Tunisian patients. Bull Cancer 2008;95:E1–4.
  • 30. Luo YP, Chen HC, Khan MA, Chen FZ, Wan XX, Tan B, et al. Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility. Tumour Biol 2011;32:215–22.
  • 31. Aydin-Sayitoglu M, Hatirnaz O, Erensoy N, Ozbek U. Role of CYP2D6, CYP1A1, CYP2E1, GSTT1 and GSTM1 genes in the susceptibility to acute leukaemias. Am J Hematol 2006;81:162–70.
  • 32. Binkhorst L, Mathijssen RH, Jager A, Gelder T. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping. Canc Treat Rev 2015;41:289–99.
  • 33. Györffy B, Kocsis I, Vásárhelyi B. Biallelic genotype distributions in papers published in Gut between 1998 and 2003: altered conclusions after recalculating the Hardy-Weinberg equilibrium. Gut 2004;53:614–6.
  • 34. Wang J, Shete S. Testing departure from Hardy-Weinberg proportions. Methods Mol Biol 2012;850:77–102.
APA Daglar Aday A, Ozturk T, TEKER B, AKSOY F, Yilmaz Aydogan H, Öztürk O, İsbir T (2021). Association of CYP2D6*4 gene polymorphism with early papillary thyroid carcinoma. , 455 - 460. 10.1515/tjb-2020-0103
Chicago Daglar Aday Aynur,Ozturk Tulin,TEKER Başak Akadam,AKSOY Figen,Yilmaz Aydogan Hulya,Öztürk Oğuz,İsbir Turgay Association of CYP2D6*4 gene polymorphism with early papillary thyroid carcinoma. (2021): 455 - 460. 10.1515/tjb-2020-0103
MLA Daglar Aday Aynur,Ozturk Tulin,TEKER Başak Akadam,AKSOY Figen,Yilmaz Aydogan Hulya,Öztürk Oğuz,İsbir Turgay Association of CYP2D6*4 gene polymorphism with early papillary thyroid carcinoma. , 2021, ss.455 - 460. 10.1515/tjb-2020-0103
AMA Daglar Aday A,Ozturk T,TEKER B,AKSOY F,Yilmaz Aydogan H,Öztürk O,İsbir T Association of CYP2D6*4 gene polymorphism with early papillary thyroid carcinoma. . 2021; 455 - 460. 10.1515/tjb-2020-0103
Vancouver Daglar Aday A,Ozturk T,TEKER B,AKSOY F,Yilmaz Aydogan H,Öztürk O,İsbir T Association of CYP2D6*4 gene polymorphism with early papillary thyroid carcinoma. . 2021; 455 - 460. 10.1515/tjb-2020-0103
IEEE Daglar Aday A,Ozturk T,TEKER B,AKSOY F,Yilmaz Aydogan H,Öztürk O,İsbir T "Association of CYP2D6*4 gene polymorphism with early papillary thyroid carcinoma." , ss.455 - 460, 2021. 10.1515/tjb-2020-0103
ISNAD Daglar Aday, Aynur vd. "Association of CYP2D6*4 gene polymorphism with early papillary thyroid carcinoma". (2021), 455-460. https://doi.org/10.1515/tjb-2020-0103
APA Daglar Aday A, Ozturk T, TEKER B, AKSOY F, Yilmaz Aydogan H, Öztürk O, İsbir T (2021). Association of CYP2D6*4 gene polymorphism with early papillary thyroid carcinoma. Türk Biyokimya Dergisi, 46(4), 455 - 460. 10.1515/tjb-2020-0103
Chicago Daglar Aday Aynur,Ozturk Tulin,TEKER Başak Akadam,AKSOY Figen,Yilmaz Aydogan Hulya,Öztürk Oğuz,İsbir Turgay Association of CYP2D6*4 gene polymorphism with early papillary thyroid carcinoma. Türk Biyokimya Dergisi 46, no.4 (2021): 455 - 460. 10.1515/tjb-2020-0103
MLA Daglar Aday Aynur,Ozturk Tulin,TEKER Başak Akadam,AKSOY Figen,Yilmaz Aydogan Hulya,Öztürk Oğuz,İsbir Turgay Association of CYP2D6*4 gene polymorphism with early papillary thyroid carcinoma. Türk Biyokimya Dergisi, vol.46, no.4, 2021, ss.455 - 460. 10.1515/tjb-2020-0103
AMA Daglar Aday A,Ozturk T,TEKER B,AKSOY F,Yilmaz Aydogan H,Öztürk O,İsbir T Association of CYP2D6*4 gene polymorphism with early papillary thyroid carcinoma. Türk Biyokimya Dergisi. 2021; 46(4): 455 - 460. 10.1515/tjb-2020-0103
Vancouver Daglar Aday A,Ozturk T,TEKER B,AKSOY F,Yilmaz Aydogan H,Öztürk O,İsbir T Association of CYP2D6*4 gene polymorphism with early papillary thyroid carcinoma. Türk Biyokimya Dergisi. 2021; 46(4): 455 - 460. 10.1515/tjb-2020-0103
IEEE Daglar Aday A,Ozturk T,TEKER B,AKSOY F,Yilmaz Aydogan H,Öztürk O,İsbir T "Association of CYP2D6*4 gene polymorphism with early papillary thyroid carcinoma." Türk Biyokimya Dergisi, 46, ss.455 - 460, 2021. 10.1515/tjb-2020-0103
ISNAD Daglar Aday, Aynur vd. "Association of CYP2D6*4 gene polymorphism with early papillary thyroid carcinoma". Türk Biyokimya Dergisi 46/4 (2021), 455-460. https://doi.org/10.1515/tjb-2020-0103